Syneos eyes ocular trials with new catalyst site network

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/dolgachov)
(Image: Getty/dolgachov)
Syneos Health has launched a Catalyst Ophthalmology Site Network to support startup and delivery of ocular clinical trials.

The Ophthalmology Site Network currently includes 24 sites across the US and Europe.

Participation in the network, which is expected to grow to more than 30 sites globally in the coming months, is by invitation only.

According to the Syneos, members have the opportunity to participate in an increased volume of ophthalmology-related trials. Additionally, sites receive a dedicated relationship manager.

The Ophthalmology Site Network also will include fully integrated central institutional review board (IRB) and reading center services.

With the addition of the newest network, the company’s Catalyst Site Program – launched in 2016 – now includes more than 100 sites across the US, UK, and APAC.

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars